Kurzfassung

Cabozantinib in Patients with locally advanced or metastatic Urothelial Cell Carcinoma who have progressed after cisplatin-based chemotherapy and anti-PD-1/PD-L1 therapy or after anti-PD-1/PD-L1 therapy only